December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Effects of FIV-Based Lentiviral Vector Transduction of Trabecular Meshwork on Aqueous Outflow Facility and In Vivo Monitoring of Expression in Cats
Author Affiliations & Notes
  • NA Loewen
    Molecular Medicine Program
    Mayo Foundation Rochester MN
  • MP Fautsch
    Department of Ophthalmology
    Mayo Foundation Rochester MN
  • CK Bahler
    Department of Ophthalmology
    Mayo Foundation Rochester MN
  • DH Johnson
    Department of Ophthalmology
    Mayo Foundation Rochester MN
  • EM Poeschla
    Molecular Medicine Program
    Mayo Foundation Rochester MN
  • Footnotes
    Commercial Relationships   N.A. Loewen, None; M.P. Fautsch, None; C.K. Bahler, None; D.H. Johnson, None; E.M. Poeschla, None. Grant Identification: NIH 1R01AI47536, EY07065 and 5Research to Prevent Blindness
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3960. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      NA Loewen, MP Fautsch, CK Bahler, DH Johnson, EM Poeschla; Effects of FIV-Based Lentiviral Vector Transduction of Trabecular Meshwork on Aqueous Outflow Facility and In Vivo Monitoring of Expression in Cats . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3960.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the effects of feline immunodeficiency virus-based lentiviral vectors (FIV vectors) on outflow facility of cultured human anterior segments and to evaluate these vectors in the anterior chambers of living cats. Methods: FIV.lacZ vectors, which we have previously shown effectively transduce a beta-galactosidase marker gene into the TM of cultured human anterior segments, and new FIV vectors encoding eGFP (FIV.egfp), were used. 3 pairs of human donor eyes were injected with 1x10^8 TU (transducing units) of FIV.lacZ (right eyes) and with a control vector (FIV.lacZ.mock, left eyes). 3 additional pairs were injected with 1x10^8 TU FIV.egfp (right eyes only). Intraocular pressure was continuously recorded for 5 days and transduction efficiency was determined as the percentage of transduced cells in all quadrants. The right eyes of 2 cats were injected with 1x10^8 TU of FIV.egfp and expression levels in the living animals were rated using gonioscopy and biomicroscopy on a scale from 0 - 4. Results: Both FIV.egfp and FIV.lacZ resulted in high-level transduction of TM (79 ± 15% and 82.4 ± 3.6% of cells respectively) without cell loss compared to control eyes. Transduction caused only a transient 30% ± 22% (p = 0.02) decrease of outflow facility in cultured human anterior segments, lasting about 2 days. Facility in control eyes remained unchanged. 7 and 25 days after injection of cats 1 and 2 respectively, gonioscopically visualized eGFP expression was level 3-4 and localized to the TM; longer follow-up and correlative histological examination will be performed. Conclusion: High-level eGFP and beta-galactosidase expression can be achieved in TMs of cultured human eyes, with only small and transient changes in outflow facility. eGFP can be transduced into feline TMs with FIV vectors and can be visualized non-invasively in vivo.

Keywords: 601 trabecular meshwork • 419 gene transfer/gene therapy • 476 molecular biology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×